A MSP-1 de Plasmodium vivax (PvMSP-1), o principal alvo para o desenvolvimento de uma vacina contra a malária, é constituída por seis domínios altamente polimórficos flanqueados por seqüências conservadas. Apesar de evidências de que a divergência na seqüência da PvMSP-1 é está sendo mantida por mais de cinco milhões de anos por seleção balanceada exercida pela imunidade adquirida pelo hospedeiro, a especificidade dos anticorpos adquiridos naturalmente contra a PvMSP-1 ainda é pouco estudada. Este trabalho mostra que 15 proteínas recombinantes que correspondem às variantes da PvMSP-1 comumente encontradas em parasitos locais foram pouco reconhecidas por 376 indivíduos não-infectados com idade entre 5 e 90 anos expostos à malária na Amazônia rural; menos de 30% dos indivíduos tiveram anticorpos IgG detectáveis contra no mínimo uma variante dos blocos 2, 6 e 10 que foram expressas, embora 54,3% reconheceram o domínio conservado C-terminal PvMSP-119. Apesar da proporção de respondedores às variantes da PvMSP-1 ter aumentado substancialmente durante infecções agudas subseqüentes por P. vivax, os anticorpos não foram necessariamente específicos para as variantes da PvMSP-1 encontradas nos parasitos infectantes. São discutidos a contribuição relativa do polimorfismo antigênico, a fraca imunogenicidade e o pecado antigênico original (a tendência de a exposição a uma nova variante antigênica induzir resposta de anticorpos com especificidade pré-existente) para os padrões observados de reconhecimento por anticorpos da PvMSP-1. É sugerido que a resposta de anticorpos ao repertório de domínios variáveis da PvMSP-1 em indivíduos continuamente expostos é induzida somente após algumas infecções repetidas e requerem re-estímulo freqüente, com claras implicações para o desenvolvimento de subunidades de vacinas baseadas na PvMSP-1. / The merozoite surface protein 1 of Plasmodium vivax (PvMSP-1), a major target for malaria vaccine development, contains six highly polymorphic domains interspersed with conserved sequences. Although there is evidence that the sequence divergence in PvMSP-1 has been maintained over five million years by balanced selection exerted by host?s acquired immunity, the variant-specificity of naturally acquired antibodies to PvMSP-1 remains little investigated. Here we show that 15 recombinant proteins corresponding to PvMSP-1 variants commonly found in local parasites were poorly recognized by 376 noninfected subjects aged 5-90 years exposed to malaria in rural Amazonia; less than onethird of them had detectable IgG antibodies to at least one variant of blocks 2, 6 and 10 that were expressed, although 54.3% recognized the invariant C-terminal domain PvMSP-119. Although the proportion of responders to PvMSP-1 variants increased substantially during subsequent acute P. vivax infections, the specificity of IgG antibodies did not necessarily match the PvMSP-1 variant(s) found in infecting parasites. We discuss the relative contribution of antigenic polymorphism, poor immunogenicity, and original antigenic sin (the skew in the specificity of antibodies elicited by exposure to new antigenic variants due to preexisting variant-specific responses) to the observed patterns of antibody recognition of PvMSP-1. We suggest that antibody responses to the repertoire of variable domains of PvMSP-1 to which subjects are continuously exposed are only elicited after several repeated infections and may require frequent boosting, with clear implications for the development of PvMSP-1-based subunit vaccines.

A MSP-1 de Plasmodium vivax (PvMSP-1), o principal alvo para o desenvolvimento de uma vacina contra a malária, é constituída por seis domínios altamente polimórficos flanqueados por seqüências conservadas. Apesar de evidências de que a divergência na seqüência da PvMSP-1 é está sendo mantida por mais de cinco milhões de anos por seleção balanceada exercida pela imunidade adquirida pelo hospedeiro, a especificidade dos anticorpos adquiridos naturalmente contra a PvMSP-1 ainda é pouco estudada. Este trabalho mostra que 15 proteínas recombinantes que correspondem às variantes da PvMSP-1 comumente encontradas em parasitos locais foram pouco reconhecidas por 376 indivíduos não-infectados com idade entre 5 e 90 anos expostos à malária na Amazônia rural; menos de 30% dos indivíduos tiveram anticorpos IgG detectáveis contra no mínimo uma variante dos blocos 2, 6 e 10 que foram expressas, embora 54,3% reconheceram o domínio conservado C-terminal PvMSP-119. Apesar da proporção de respondedores às variantes da PvMSP-1 ter aumentado substancialmente durante infecções agudas subseqüentes por P. vivax, os anticorpos não foram necessariamente específicos para as variantes da PvMSP-1 encontradas nos parasitos infectantes. São discutidos a contribuição relativa do polimorfismo antigênico, a fraca imunogenicidade e o pecado antigênico original (a tendência de a exposição a uma nova variante antigênica induzir resposta de anticorpos com especificidade pré-existente) para os padrões observados de reconhecimento por anticorpos da PvMSP-1. É sugerido que a resposta de anticorpos ao repertório de domínios variáveis da PvMSP-1 em indivíduos continuamente expostos é induzida somente após algumas infecções repetidas e requerem re-estímulo freqüente, com claras implicações para o desenvolvimento de subunidades de vacinas baseadas na PvMSP-1. / The merozoite surface protein 1 of Plasmodium vivax (PvMSP-1), a major target for malaria vaccine development, contains six highly polymorphic domains interspersed with conserved sequences. Although there is evidence that the sequence divergence in PvMSP-1 has been maintained over five million years by balanced selection exerted by host?s acquired immunity, the variant-specificity of naturally acquired antibodies to PvMSP-1 remains little investigated. Here we show that 15 recombinant proteins corresponding to PvMSP-1 variants commonly found in local parasites were poorly recognized by 376 noninfected subjects aged 5-90 years exposed to malaria in rural Amazonia; less than onethird of them had detectable IgG antibodies to at least one variant of blocks 2, 6 and 10 that were expressed, although 54.3% recognized the invariant C-terminal domain PvMSP-119. Although the proportion of responders to PvMSP-1 variants increased substantially during subsequent acute P. vivax infections, the specificity of IgG antibodies did not necessarily match the PvMSP-1 variant(s) found in infecting parasites. We discuss the relative contribution of antigenic polymorphism, poor immunogenicity, and original antigenic sin (the skew in the specificity of antibodies elicited by exposure to new antigenic variants due to preexisting variant-specific responses) to the observed patterns of antibody recognition of PvMSP-1. We suggest that antibody responses to the repertoire of variable domains of PvMSP-1 to which subjects are continuously exposed are only elicited after several repeated infections and may require frequent boosting, with clear implications for the development of PvMSP-1-based subunit vaccines.

Malaria, caused by the Plasmodium parasite and transmitted by mosquitoes, kills almost half a million people each year. Drug resistance in both the parasite and its vector make preventative measures increasingly important, and a fully protective vaccine is absolutely necessary to eradicate the disease. However, genetic diversity of the parasite makes vaccine development difficult. One of the best vaccine candidates is MSP2, a surface protein present during the blood stage of P. falciparum infection. Antibodies, which are important for natural immunity, have been shown to bind MSP2 and prevent parasite infection of blood cells. The purpose of this study was to analyze MSP2 sequence diversity in a cohort of patients infected while traveling or living in sub-Saharan Africa, and to investigate patient antibody responses to MSP2 variants infecting other individuals. Parasite isolates from our cohort were made up of 47% 3D7 alleles and 53% FC27 alleles. Protein sequences showed similar levels of conservation within allelic families, and blocks of conserved amino acids between different variants suggest there may be epitopes that can induce antibody production targeting multiple variants. Antibody reactivity tests suggest the variable region of MSP2 is important for antibody binding to variants of the same allelic type, while the conserved region is important for reactivity to different allelic types. This thesis gives evidence to the importance of including epitopes from conserved and variable regions of both MSP2 allelic families in order to induce strain-transcending immunity against P. falciparum malaria. / A genomic surveillance platform for indel-rich genes from Plasmodium spp. using long-read amplicon sequencing

Diversas proteínas de superfície de merozoítas (MSPs) de Plasmodium têm sido consideradas candidatas a compor uma vacina contra a malária. Nos últimos anos estudamos diversos aspectos da resposta imune naturalmente adquirida contra proteínas recombinantes baseadas nas MSPs de P. vivax. Estes estudos demonstraram que estas proteínas recombinantes mantêm suas funções imunológicas, podendo servir como base para a caracterização de suas estruturas tridimensionais. Com o objetivo de obter informações estruturais sobre as MSPs de P. vivax, 10 proteínas recombinantes, correspondentes à região C-terminal da MSP-1 (MSP119), e diferentes regiões da MSP-3α e MSP-3β foram expressas em Escherichia coli. Os dados estruturais da MSP119 foram obtidos por modelagem molecular com base nas coordenadas cristalográficas da MSP19 de P. cynomolgi. Por outro lado, existem poucas informações estruturais sobre as proteínas da família MSP-3 de Plasmodium. A análise da estrutura primária dessas proteínas indica que elas apresentam um domínio central rico em alaninas que estão organizadas como motivos \"heptads\". Esse tipo de estrutura primária favorece a formação de estruturas do tipo α-hélices e \"coiled-coil\" (CC). No presente estudo, a composição da estrutura secundária de cada proteína recombinante foi caracterizada preliminarmente por ensaio de Dicroísmo Circular, realizado na região do UV distante. Com base nos resultados obtidos, selecionamos duas proteínas recombinantes baseadas na região C-terminal da MSP-3α (CC4 e CC5) para análises biofísicas mais detalhadas. Inicialmente, demonstramos por espectrometria de massa que ambas as proteínas têm massa molecular esperada. Entretanto, os dados obtidos por cromatografia em gel filtração sugeriram que essas proteínas formam oligômeros. No caso específico da proteína CC5, estes dados foram confirmados por ultracentrifugação analítica que indicou a formação de tetrâmeros elongados, corroborando com a formação de estrutura do tipo \"coiled-coil\". Como o papel biológico dessas proteínas não é conhecido, os dados estruturais obtidos neste estudo podem servir como base para o entendimento da função dessas proteínas. Na segunda parte deste projeto, selecionamos cinco proteínas recombinantes para estudos comparativos de reconhecimento por anticorpos IgG de indivíduos procedentes de áreas endêmicas de malária vivax. Tais estudos confirmaram dados prévios que as MSPs são imunogênicas em infecções naturais. Em conjunto, nossos resultados sugerem que, assim como a MSP119, proteínas recombinantes baseadas na MSP-3a e MSP-313 podem ser exploradas em futuros estudos de indução de imunidade protetora contra a malária vivax em primatas não humanos. / Several merozoite surface proteins (MSPs) of Plasmodium have been considered candidates to compose a vaccine against malaria. In the last years, we have studied severaI aspects of the natural/y acquired immune response against recombinant proteins based on MSPs of P. vivax. These studies demonstrated that the recombinant proteins maintain their immunological functions and could be used for the characterization of their three-dimensional structure. To gain structural information on the MSPs of P. vivax, 10 recombinant proteins corresponding to the C-terminal region of MSP-1 (MSP119) and to different regions of the MSP-3α and MSP-3β were expressed in Escherichia coli. The structural data of the MSP119 were obtained by molecular modeling based on the crystallographic coordinates of the P. cynomolgi MSP119. On the other hand, there is limited structural information available for MSP-3 family of Plasmodium. The analysis of the primary structure of these proteins indicates that they present a central alanine-rich domain organized as heptads repeats. This type of primary structure favors the formation of α-helices and coiled-coil (CC) structures. In the present study, the composition of the secondary structure of each recombinant protein was characterized preliminarily by circular dichroism monitored in the far-UV region. On the basis of the obtained results, we selected two recombinant proteins based on C-terminal region of the MSP-3α (CC4 and CC5) for detailed biophysical analyses. Initially, we demonstrated that the monomer mass assigned for the two recombinant proteins corresponded exactly to those predicted from the primary sequence. However, during size exclusion chromatography, the proteins eluted at volumes corresponding to molecular weights that were much larger than their monomeric masses, suggesting that both proteins are oligomeric molecules. Interestingly, analytical ultracentrifugation experiments showed that the CC5 oligomers are elongated molecules. As the function of these proteins is not known, the structural data obtained in this study can be used to understand the function of these proteins. In the second part of this study, we selected five recombinant proteins for comparative recognition by IgG antibodies of the individuais from endemic areas of malaria vivax. These studies confirmed previous data that the MSPs are imunogenic in natural infections. Together, our results suggest that, as well as the MSP119, that recombinant proteins based on the MSP-3α and MSP-3β can be explored in future studies for the induction of protective immunity against malaria vivax.

Diversas proteínas de superfície de merozoítas (MSPs) de Plasmodium têm sido consideradas candidatas a compor uma vacina contra a malária. Nos últimos anos estudamos diversos aspectos da resposta imune naturalmente adquirida contra proteínas recombinantes baseadas nas MSPs de P. vivax. Estes estudos demonstraram que estas proteínas recombinantes mantêm suas funções imunológicas, podendo servir como base para a caracterização de suas estruturas tridimensionais. Com o objetivo de obter informações estruturais sobre as MSPs de P. vivax, 10 proteínas recombinantes, correspondentes à região C-terminal da MSP-1 (MSP119), e diferentes regiões da MSP-3α e MSP-3β foram expressas em Escherichia coli. Os dados estruturais da MSP119 foram obtidos por modelagem molecular com base nas coordenadas cristalográficas da MSP19 de P. cynomolgi. Por outro lado, existem poucas informações estruturais sobre as proteínas da família MSP-3 de Plasmodium. A análise da estrutura primária dessas proteínas indica que elas apresentam um domínio central rico em alaninas que estão organizadas como motivos \"heptads\". Esse tipo de estrutura primária favorece a formação de estruturas do tipo α-hélices e \"coiled-coil\" (CC). No presente estudo, a composição da estrutura secundária de cada proteína recombinante foi caracterizada preliminarmente por ensaio de Dicroísmo Circular, realizado na região do UV distante. Com base nos resultados obtidos, selecionamos duas proteínas recombinantes baseadas na região C-terminal da MSP-3α (CC4 e CC5) para análises biofísicas mais detalhadas. Inicialmente, demonstramos por espectrometria de massa que ambas as proteínas têm massa molecular esperada. Entretanto, os dados obtidos por cromatografia em gel filtração sugeriram que essas proteínas formam oligômeros. No caso específico da proteína CC5, estes dados foram confirmados por ultracentrifugação analítica que indicou a formação de tetrâmeros elongados, corroborando com a formação de estrutura do tipo \"coiled-coil\". Como o papel biológico dessas proteínas não é conhecido, os dados estruturais obtidos neste estudo podem servir como base para o entendimento da função dessas proteínas. Na segunda parte deste projeto, selecionamos cinco proteínas recombinantes para estudos comparativos de reconhecimento por anticorpos IgG de indivíduos procedentes de áreas endêmicas de malária vivax. Tais estudos confirmaram dados prévios que as MSPs são imunogênicas em infecções naturais. Em conjunto, nossos resultados sugerem que, assim como a MSP119, proteínas recombinantes baseadas na MSP-3a e MSP-313 podem ser exploradas em futuros estudos de indução de imunidade protetora contra a malária vivax em primatas não humanos. / Several merozoite surface proteins (MSPs) of Plasmodium have been considered candidates to compose a vaccine against malaria. In the last years, we have studied severaI aspects of the natural/y acquired immune response against recombinant proteins based on MSPs of P. vivax. These studies demonstrated that the recombinant proteins maintain their immunological functions and could be used for the characterization of their three-dimensional structure. To gain structural information on the MSPs of P. vivax, 10 recombinant proteins corresponding to the C-terminal region of MSP-1 (MSP119) and to different regions of the MSP-3α and MSP-3β were expressed in Escherichia coli. The structural data of the MSP119 were obtained by molecular modeling based on the crystallographic coordinates of the P. cynomolgi MSP119. On the other hand, there is limited structural information available for MSP-3 family of Plasmodium. The analysis of the primary structure of these proteins indicates that they present a central alanine-rich domain organized as heptads repeats. This type of primary structure favors the formation of α-helices and coiled-coil (CC) structures. In the present study, the composition of the secondary structure of each recombinant protein was characterized preliminarily by circular dichroism monitored in the far-UV region. On the basis of the obtained results, we selected two recombinant proteins based on C-terminal region of the MSP-3α (CC4 and CC5) for detailed biophysical analyses. Initially, we demonstrated that the monomer mass assigned for the two recombinant proteins corresponded exactly to those predicted from the primary sequence. However, during size exclusion chromatography, the proteins eluted at volumes corresponding to molecular weights that were much larger than their monomeric masses, suggesting that both proteins are oligomeric molecules. Interestingly, analytical ultracentrifugation experiments showed that the CC5 oligomers are elongated molecules. As the function of these proteins is not known, the structural data obtained in this study can be used to understand the function of these proteins. In the second part of this study, we selected five recombinant proteins for comparative recognition by IgG antibodies of the individuais from endemic areas of malaria vivax. These studies confirmed previous data that the MSPs are imunogenic in natural infections. Together, our results suggest that, as well as the MSP119, that recombinant proteins based on the MSP-3α and MSP-3β can be explored in future studies for the induction of protective immunity against malaria vivax.

Ma thèse s'inscrit dans l'étude des modifications du globule rouge humain induites par P. falciparum. Ces modifications qui représentent une remarquable adaptation du parasite à un environnement plus complexe qu'il n'y paraît au premier abord et expliquent sa persistance chez l'Homme sont détaillées dans une revue et un chapitre de livre dont je suis co-auteur. Mes travaux de recherche ont porté sur la caractérisation fonctionnelle des structures de Maurer, un compartiment membranaire exporté par le parasite dans le globule rouge parasitaire et directement lié à la physiopathologie du paludisme grave. J'ai contribué à la caractérisation fonctionnelle de nouvelles protéines de ces structures, codées par trois familles multigéniques sub-télomériques en cluster avec la famille Pfmc-2tm, et présentant de façon étonnante un fort degré de conservation (article 1). La diminution d'expression de ces gènes, obtenue par titration d'un facteur transcriptionnel, entraine un défaut de libération des mérozoïtes. Mon deuxième projet porte sur l'identification des modalités d'export de la protéine transmembranaire résidente des structures de Maurer PfSBP1. Mes travaux montrent que PfSBP1 est exportée sous forme soluble dans le cytoplasme érythrocytaire, en interaction avec le complexe chaperon parasitaire PfTCP1 (article 2). / Plasmodium falciparum causes the most severe forms of human malaria, a pathology associated with the erythrocytic asexual stages of the parasite. My work focused on the remodeling of the infected erythrocytes induced by P. falciparum and detailed in a review and a book chapter that I co-authored. These modifications illustrate a remarkable adaptation of P. falciparum resulting in its persistence in humans. My PhD thesis was dedicated to the functional characterization of Maurer's clefts, a membrane compartment transposed by the parasite in the cytoplasm of its host cell, and central to the export of virulence factors to the host cell surface. I have conducted two projects and contributed first to the functional characterization of novel exported protein encoded by three highly conserved multigene sub-telomeric families in cluster with the Pfmc-2tm family. Down regulation of these gene families by promoter titration impacted the release of infectious merozoites from the host cell (annex 1). My second project was dedicated to the identification of the modality of export of the resident and Maurer's clefts transmembrane protein PfSBP1. I have shown that PfSBP1 is exported as a soluble protein in the host cell cytoplasm in interaction with the parasite Thermosome complex protein 1 (PfTCP1) chaperone complex (annex 2).

by Ng Wang Kit. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 131-139). / Abstracts in English and Chinese. / Acknowledgements --- p.iii / Abstract --- p.v / List of Tables --- p.ix / List of Figures --- p.x / List of Abbreviations --- p.xiii / Table of Contents --- p.xv / Chapter Chapter 1: --- General Introduction --- p.1 / Chapter Chapter 2: --- Literature Review --- p.3 / Chapter 2.1 --- Malaria --- p.3 / Chapter 2.1.1 --- Global picture --- p.3 / Chapter 2.1.2 --- Malaria mechanics --- p.4 / Chapter 2.1.3 --- Life cycle of malaria parasite --- p.4 / Chapter 2.2 --- Treatment of malaria ´ؤ malaria drugs --- p.5 / Chapter 2.2.1 --- Antimalarial drugs --- p.5 / Chapter 2.2.2 --- Drug resistance --- p.6 / Chapter 2.3 --- Treatment of malaria - malarial vaccines --- p.7 / Chapter 2.3.1 --- Malarial vaccine developments --- p.7 / Chapter 2.3.2 --- Transmission blocking vaccines --- p.7 / Chapter 2.3.3 --- Pre-erythrocytic vaccines --- p.9 / Chapter 2.3.4 --- Blood stage vaccines --- p.10 / Chapter 2.4 --- The major merozoite protein - gpl95 --- p.11 / Chapter 2.5 --- Plants as bioreactors --- p.12 / Chapter 2.5.1 --- Products of transgenic plants --- p.13 / Chapter 2.6 --- Transgenic plants for production of subunit vaccines --- p.14 / Chapter 2.6.1 --- Norwalk virus capsid protein production --- p.15 / Chapter 2.6.2 --- Hepatitis B surface antigen production --- p.15 / Chapter 2.7 --- Tobacco and Arabidopsis as model plants --- p.16 / Chapter 2.7.1 --- Arabidopsis --- p.16 / Chapter 2.7.2 --- Tobacco --- p.17 / Chapter 2.8 --- Transformation methods --- p.17 / Chapter 2.8.1 --- Direct DNA uptake --- p.17 / Chapter 2.8.1.1 --- Plant protoplast transformation --- p.17 / Chapter 2.8.1.2 --- Biolistic transformation --- p.18 / Chapter 2.8.2 --- Agrobacterium-mediated transformation --- p.18 / Chapter 2.8.2.1 --- Leaf-disc technique --- p.18 / Chapter 2.8.2.2 --- In planta transformation --- p.19 / Chapter 2.9 --- Phaseolin --- p.20 / Chapter 2.10 --- Detection and purification of recombinant products - Histidine tag --- p.21 / Chapter 2.11 --- Aims of study and hypotheses --- p.22 / Chapter Chapter 3: --- Materials and Methods --- p.24 / Chapter 3.1 --- Introduction --- p.24 / Chapter 3.2 --- Chemicals --- p.24 / Chapter 3.3 --- Expression in tobacco system --- p.24 / Chapter 3.3.1 --- Plant materials --- p.24 / Chapter 3.3.2 --- Bacterial strains --- p.25 / Chapter 3.3.3 --- Chimeric gene construction for tobacco transformation --- p.25 / Chapter 3.3.3.1 --- The cloning of pTZPhasp/flgp42-His/Phast (F1) --- p.26 / Chapter 3.3.3.2 --- The cloning of pBKPhasp-sp/flgp42-His/Phast (P9) --- p.30 / Chapter 3.3.3.3 --- The cloning of pHM2Ubip/flgp42-His/Nost (C2) --- p.30 / Chapter 3.3.4 --- Confirmation of sequence fidelity of chimeric gene by DNA sequencing --- p.33 / Chapter 3.3.5 --- Cloning of chimeric gene into binary vector --- p.34 / Chapter 3.3.6 --- Triparental mating of Agrobacterium tumefaciens LBA4404/pAL4404 --- p.35 / Chapter 3.3.7 --- Tobacco transformation and regeneration --- p.36 / Chapter 3.3.8 --- GUS assay --- p.37 / Chapter 3.3.9 --- Genomic DNA isolation --- p.37 / Chapter 3.3.10 --- PCR amplification and detection of transgene --- p.38 / Chapter 3.3.11 --- Southern blot analysis --- p.38 / Chapter 3.3.12 --- Total seeds RNA isolation --- p.39 / Chapter 3.3.13 --- RT-PCR --- p.39 / Chapter 3.3.14 --- Northern blot analysis --- p.40 / Chapter 3.3.15 --- Protein extraction and SDS-PAGE --- p.40 / Chapter 3.3.16 --- Western blot analysis --- p.41 / Chapter 3.4 --- Expression in Arabidopsis system --- p.42 / Chapter 3.4.1 --- Plant materials --- p.42 / Chapter 3.4.2 --- Bacterial strains --- p.42 / Chapter 3.4.3 --- Chimeric gene construction --- p.42 / Chapter 3.4.3.1 --- The cloning of pBKPhasp-sp/His/EK/p42/Phast (DH) --- p.43 / Chapter 3.4.3.2 --- The cloning of pTZPhaSp/His/EK/p42/Phast (EH) --- p.45 / Chapter 3.4.3.3 --- The cloning of pBKPhasp-sp/His/EK/flgp42/Phast (DHF) and pTZPhasp/His/EK/flgp42/Phast (EHF) --- p.45 / Chapter 3.4.4 --- Confirmation of sequence fidelity of chimeric genes --- p.45 / Chapter 3.4.5 --- Cloning of chimeric gene into Agrobacterium binary vector --- p.49 / Chapter 3.4.6 --- Transformation of Agrobacterium tumefaciens GV3101/pMP90 with chimeric gene constructs --- p.49 / Chapter 3.4.7 --- Arabidopsis Transformation --- p.49 / Chapter 3.4.8 --- Vacuum infiltration transformation --- p.50 / Chapter 3.4.9 --- Selection of successful transformants --- p.51 / Chapter 3.4.10 --- Selection for homozygous plants with single gene insertion --- p.51 / Chapter 3.4.11 --- GUS assay --- p.52 / Chapter 3.4.12 --- Genomic DNA isolation --- p.52 / Chapter 3.4.13 --- PCR amplification and detection of transgenes --- p.52 / Chapter 3.4.14 --- Southern Blot analysis --- p.52 / Chapter 3.4.15 --- Total siliques RNA isolation --- p.53 / Chapter 3.4.16 --- RT-PCR --- p.53 / Chapter 3.4.17 --- Northern blot analysis --- p.53 / Chapter 3.4.17 --- Protein extraction and SDS-PAGE --- p.54 / Chapter 3.4.18 --- Western blot analysis --- p.54 / Chapter 3.5 --- In vitro transcription and translation --- p.54 / Chapter 3.5.1 --- In vitro transcription --- p.54 / Chapter 3.5.2 --- In vitro translation --- p.55 / Chapter 3.6 --- Particle bombardment of GUS fusion gene --- p.56 / Chapter 3.6.1 --- Chimeric gene constructs --- p.56 / Chapter 3.6.2 --- Particle bombardment using snow bean cotyledon --- p.61 / Chapter Chapter 4: --- Results --- p.63 / Chapter 4.1 --- Tobacco system --- p.63 / Chapter 4.1.1 --- Chimeric gene constructs --- p.63 / Chapter 4.1.2 --- Tobacco transformation and regeneration --- p.65 / Chapter 4.1.3 --- GUS activity assay --- p.67 / Chapter 4.1.4 --- Molecular analysis of transgene integration --- p.68 / Chapter 4.1.4.1 --- Genomic DNA extraction and PCR --- p.68 / Chapter 4.1.4.2 --- Southern blot analysis --- p.70 / Chapter 4.1.5 --- Molecular analysis of transgene expression --- p.72 / Chapter 4.1.5.1 --- Total RNA isolation and RT-PCR --- p.72 / Chapter 4.1.5.2 --- Northern blot analysis --- p.75 / Chapter 4.1.6 --- Genomic PCR to confirm whole gene transfer --- p.76 / Chapter 4.1.7 --- Biochemical analysis of transgene expression --- p.78 / Chapter 4.1.7.1 --- Protein extraction and SDS-PAGE --- p.78 / Chapter 4.1.7.2 --- Western blot analysis --- p.78 / Chapter 4.2 --- Arabidopsis system --- p.83 / Chapter 4.2.1 --- Chimeric gene constructs --- p.83 / Chapter 4.2.2 --- Arabidopsis transformation and selection --- p.85 / Chapter 4.2.3 --- Selection of transgenic plants --- p.87 / Chapter 4.2.4 --- Assay of GUS activity --- p.91 / Chapter 4.2.5 --- Molecular analysis of transgene integration --- p.92 / Chapter 4.2.5.1 --- Genomic DNA extraction and PCR --- p.92 / Chapter 4.2.5.2 --- Southern blot analysis --- p.96 / Chapter 4.2.6 --- Molecular analysis of transgene expression --- p.99 / Chapter 4.2.6.1 --- Total RNA isolation and RT-PCR --- p.99 / Chapter 4.2.6.2 --- Northern blot analysis --- p.106 / Chapter 4.2.7 --- Genomic PCR for confirmation of whole gene transfer --- p.107 / Chapter 4.2.8 --- Biochemical analysis of transgene expression --- p.108 / Chapter 4.2.8.1 --- Protein extraction and SDS-PAGE --- p.108 / Chapter 4.2.8.2 --- Western blot analysis --- p.108 / Chapter 4.3 --- In vitro transcription and translation --- p.112 / Chapter 4.4 --- Particle bombardment of p42/ GUS fusion gene --- p.115 / Chapter Chapter 5: --- Discussion and Future perspectives --- p.117 / Chapter 5.1 --- Failure in detecting transgene expression --- p.117 / Chapter 5.2 --- Poor transgene expression --- p.120 / Chapter 5.2.1 --- Bacillus thuringiensis toxin and green fluorescent protein --- p.120 / Chapter 5.2.2 --- AT-richness --- p.121 / Chapter 5.2.3 --- Deleterious sequence - AUUUA --- p.123 / Chapter 5.2.4 --- Presence of AAUAAA or AAUAAA-like motifs --- p.125 / Chapter 5.2.5 --- Codon usage --- p.126 / Chapter 5.3 --- Future perspectives --- p.127 / Chapter Chapter 6: --- Conclusion --- p.129 / References --- p.131

O objetivo deste trabalho foi estudar a resposta imune, quanto ao nível e à avidez dos anticorpos IgG, dirigidos contra o antígeno recombinante derivada da Proteína 1 de Superfície de Merozoíto de Plasmodium vivax (PvMSP119) em indivíduos residentes em diferentes áreas endêmicas do Brasil, empregando o teste ELISA. Para tanto, foram estudadas amostras de indivíduos expostos à malária, infectados ou não e em acompanhamento terapêutico. Na padronização das condições de reação, obteve-se uma sensibilidade de 95,00% em amostras de pacientes com gota espessa positiva para P. vivax e uma especificidade de 99,50% em amostras de indivíduos saudáveis e com outras patologias. Entre as amostras de pacientes com P. falciparum, 7,14% foram reagentes. O estudo dos diferentes grupos de pacientes com malária vivax mostrou haver diferença significante entre os primo infectados e aqueles com episódios anteriores de malária, sendo os níveis (IR) e avidez (IA) de IgG mais baixos nos primo infectados, embora os níveis de anticorpos já estivessem elevados nesses pacientes. A predominância de IgG anti-PvMSP119 de baixa avidez nos pacientes primo infectados por P. vivax, sugere um baixo grau de proteção, mesmo na presença de elevados níveis de anticorpos observados já no início da infecção. A análise dos indivíduos não infectados mostrou haver uma associação negativa dos resultados de IR com o tempo decorrido desde o último episódio de malária e associação positiva com o número de malárias anteriores. Em relação aos IA houve associação positiva com ambos os parâmetros, nos pacientes que haviam tido malária até, no máximo, seis meses antes da coleta. Entre os pacientes que haviam apresentado episódios de malária anteriores, observaram-se níveis mais baixos de anticorpos IgG anti-PvMSP119 em indivíduos com alta exposição à malária, quando comparados a moradores de áreas com baixa transmissão. Em relação à avidez, foram encontrados índices mais elevados nas áreas de maior transmissão. Considerando-se o município de Alta Floresta, nas regiões de garimpo e próximas à mata, obtiveram-se altos índices de positividade com níveis e avidez dos anticorpos mais elevados que nas demais regiões. Não foi observada correlação entre níveis e avidez dos anticorpos IgG anti-PvMSP119. / The aim of this work was to study the level and avidity of IgG antibodies specific to Plasmodium vivax using the recombinant protein corresponding to 19kDa C-terminal of the merozoite surface protein 1 region (PvMSP119) in individuals living in distinct malaria endemic areas, using ELISA test. Thus, samples from individuals exposed to malaria, with patent infection or not were evaluated. The reaction conditions were standardized, yielding 95.00% sensitivity with sera from P. vivax infected patients and 99.50% specificity with sera from individuals non-exposed to P. vivax malaria. Just 7.14% of patient samples with P. falciparum malaria reacted to PvMSP119. The investigation of different groups of vivax malaria patients showed significant differences between patients with primo infection and those with past malaria episodes. The levels and avidity of IgG were lower in primo infected ones. The predominance of low avidity IgG in P. vivax primo infected patients may suggest low grade of protection even in high level antibody sera. The analysis of non-infected subjects showed a negative association of IgG levels and time elapsed since last malaria episode, and a positive association to the number of malaria episodes. For individuals who had had last malaria episode till maximum six months before the collecting of blood samples, avidity indexes showed positive association for both parameters described before. Individuals sporadically exposed to malaria transmission (Belém group) and who experienced their last episode by P. vivax had significant high levels and proportions of specific antibodies when compared to subjects continuously exposed (Alta Floresta group). Otherwise, higher avidity levels were detected in high transmission areas. In god mines and forest areas of Alta Floresta, higher IgG and avidity levels were obtained, as compared to the other regions of the municipality. No correlation was observed between anti-PvMSP119 IgG levels and avidity levels.

O objetivo deste trabalho foi estudar a resposta imune, quanto ao nível e à avidez dos anticorpos IgG, dirigidos contra o antígeno recombinante derivada da Proteína 1 de Superfície de Merozoíto de Plasmodium vivax (PvMSP119) em indivíduos residentes em diferentes áreas endêmicas do Brasil, empregando o teste ELISA. Para tanto, foram estudadas amostras de indivíduos expostos à malária, infectados ou não e em acompanhamento terapêutico. Na padronização das condições de reação, obteve-se uma sensibilidade de 95,00% em amostras de pacientes com gota espessa positiva para P. vivax e uma especificidade de 99,50% em amostras de indivíduos saudáveis e com outras patologias. Entre as amostras de pacientes com P. falciparum, 7,14% foram reagentes. O estudo dos diferentes grupos de pacientes com malária vivax mostrou haver diferença significante entre os primo infectados e aqueles com episódios anteriores de malária, sendo os níveis (IR) e avidez (IA) de IgG mais baixos nos primo infectados, embora os níveis de anticorpos já estivessem elevados nesses pacientes. A predominância de IgG anti-PvMSP119 de baixa avidez nos pacientes primo infectados por P. vivax, sugere um baixo grau de proteção, mesmo na presença de elevados níveis de anticorpos observados já no início da infecção. A análise dos indivíduos não infectados mostrou haver uma associação negativa dos resultados de IR com o tempo decorrido desde o último episódio de malária e associação positiva com o número de malárias anteriores. Em relação aos IA houve associação positiva com ambos os parâmetros, nos pacientes que haviam tido malária até, no máximo, seis meses antes da coleta. Entre os pacientes que haviam apresentado episódios de malária anteriores, observaram-se níveis mais baixos de anticorpos IgG anti-PvMSP119 em indivíduos com alta exposição à malária, quando comparados a moradores de áreas com baixa transmissão. Em relação à avidez, foram encontrados índices mais elevados nas áreas de maior transmissão. Considerando-se o município de Alta Floresta, nas regiões de garimpo e próximas à mata, obtiveram-se altos índices de positividade com níveis e avidez dos anticorpos mais elevados que nas demais regiões. Não foi observada correlação entre níveis e avidez dos anticorpos IgG anti-PvMSP119. / The aim of this work was to study the level and avidity of IgG antibodies specific to Plasmodium vivax using the recombinant protein corresponding to 19kDa C-terminal of the merozoite surface protein 1 region (PvMSP119) in individuals living in distinct malaria endemic areas, using ELISA test. Thus, samples from individuals exposed to malaria, with patent infection or not were evaluated. The reaction conditions were standardized, yielding 95.00% sensitivity with sera from P. vivax infected patients and 99.50% specificity with sera from individuals non-exposed to P. vivax malaria. Just 7.14% of patient samples with P. falciparum malaria reacted to PvMSP119. The investigation of different groups of vivax malaria patients showed significant differences between patients with primo infection and those with past malaria episodes. The levels and avidity of IgG were lower in primo infected ones. The predominance of low avidity IgG in P. vivax primo infected patients may suggest low grade of protection even in high level antibody sera. The analysis of non-infected subjects showed a negative association of IgG levels and time elapsed since last malaria episode, and a positive association to the number of malaria episodes. For individuals who had had last malaria episode till maximum six months before the collecting of blood samples, avidity indexes showed positive association for both parameters described before. Individuals sporadically exposed to malaria transmission (Belém group) and who experienced their last episode by P. vivax had significant high levels and proportions of specific antibodies when compared to subjects continuously exposed (Alta Floresta group). Otherwise, higher avidity levels were detected in high transmission areas. In god mines and forest areas of Alta Floresta, higher IgG and avidity levels were obtained, as compared to the other regions of the municipality. No correlation was observed between anti-PvMSP119 IgG levels and avidity levels.

Thesis (Ph. D.)--Uniformed Services University of the Health Sciences, 2005. / Typescript (photocopy).